FairJourney Bio has partnered with AbTherx to bring transgenic mouse-based antibody discovery capabilities into its integrated discovery platform.

FairJourney Bio has entered a partnership with AbTherx that will allow the company to offer transgenic mouse-based antibody discovery as part of its end-to-end antibody development services.

The agreement gives FairJourney Bio access to AbTherx’s Atlas Full Human Diversity and Common Light Chain mouse technologies, enabling programmes to move from immunisation through antibody screening, optimisation and developability assessment within a single workflow.

The companies said the partnership is intended to reduce the need for multiple service providers during antibody discovery and development programmes.

Under the arrangement, antibody discovery projects can be conducted across FairJourney Bio’s sites in Porto, Cambridge and San Diego, covering activities from immunisation and single B-cell screening through to candidate stability assessment and cell-line development.

The Atlas mouse technologies were developed to generate fully human antibodies with broad diversity and are designed to support the discovery of therapeutic antibody candidates with favourable development characteristics.

FairJourney Bio said the technology will be integrated with its B-Cell Navigator platform, which combines single B-cell screening with developability assessment.

Werner Lanthaler, chief executive officer at FairJourney Bio, said: “We are investing so a partner’s programme can run from immunisation to a developability-assessed lead inside FJBio, without changing hands.”

He added: “Following a molecule under “one roof” and with one team of scientists increases probabilities of success significantly.”

Dan Rohrer, chief technology officer at AbTherx, said: “Uniting our proprietary Full Human Diversity and Common Light Chain technologies with FairJourney Bio’s exceptional, quality-driven scientific team creates a powerful synergy.”

The partnership was announced during the BIO International Convention 2026 and comes as FairJourney Bio continues to expand its US operations, including the opening of a dedicated cryo-electron microscopy facility in San Diego.

The move reflects continued investment across the antibody discovery sector in technologies designed to improve the efficiency of therapeutic antibody identification and optimisation before candidates enter preclinical and clinical development.